Results 141 to 150 of about 8,274 (166)

Eosinophilic Cardiomyopathy in Eosinophilic Granulomatosis With Polyangiitis After Dupilumab Therapy. [PDF]

JACC Case Rep
Agredano I, Michiels V, Argacha JF, Verbrugge FH, Tanaka K, Lefesvre P, Cosyns B.   +6 more
europepmc   +1 more source

Case Report: Secondary syphilis with pulmonary involvement mimicking eosinophilic granulomatosis with polyangiitis - targeted next-generation sequencing as an adjunct in resolving an atypical non-exanthematous presentation. [PDF]

Front Med (Lausanne)
Tang S, Zhang T, Hao A, Su B, Liu B.
europepmc   +1 more source

Case Report: Benralizumab combined with a steroid-sparing strategy in a case of severe eosinophilic granulomatosis with polyangiitis. [PDF]

Front Immunol
Zhou N, Fang C, Feng M, Dong C.
europepmc   +1 more source

The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis. [PDF]

Proc (Bayl Univ Med Cent)
Chaisrimaneepan N, Yingchoncharoen P, Sodsri T, Jakramonpreeya N, Nugent KM.   +4 more
europepmc   +1 more source

Asthma-free eosinophilic granulomatosis with polyangiitis presenting with Guillain-Barré syndrome-like symptoms: a case report. [PDF]

Front Med (Lausanne)
Huang H, Zhao X, Zhou Y, Chen S, Zhou Y.
europepmc   +1 more source

Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study. [PDF]

BMC Pulm Med
Kaburaki S, Tanaka T, Kamio K, Tanaka Y, Taniuchi N, Kasahara K, Seike M.   +6 more
europepmc   +1 more source

ANCA-Negative EGPA: Only Eosinophils Without Vasculitis? Insights From Anti-T2 Biologics [PDF]

Frontiers in Immunology, 2023
The pathogenic role of p-ANCA in eosinophilic granulomatosis with polyangiitis (EGPA) is a long-standing matter of debate. In this work, we report our real-life experience with EGPA patients, treated with biologics targeting type 2 (T2)-eosinophilic ...
Matteo Martini, Gianluca Moroncini, Leonardo Antonicelli   +2 more
exaly   +2 more sources

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Frontiers in Pharmacology, 2022
Background: Traditionally, Eosinophilic Granulomatosis with Polyangiitis (EGPA) has been treated with systemic corticosteroids and immunosuppressants. In recent years, therapeutic efforts have been directed towards targeting eosinophils which represent a
Sebastiano Gangemi, Giovanni Pioggia, Luisa Ricciardi   +2 more
exaly   +2 more sources

EGPA Phenotyping: Not Only ANCA, but Also Eosinophils [PDF]

Biomedicines, 2023
Background: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a small-vessel necrotizing vasculitis. The anti-neutrophil cytoplasmic antibodies’ (ANCA) role in defining clinical EGPA phenotypes is well established.
Lorenzo Cosmi, Paola Parronchi, Oliviero Rossi   +2 more
exaly   +2 more sources

Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force Recommendations for Evaluation and Management [PDF]

European Journal of Internal Medicine, 2015
Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA).
Loïc Guillevin, Peter A Merkel
exaly   +2 more sources